Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

New study shows hepatitis C burden may ease in future

cells115x76

Anew study published in the Annals of Internal Medicine projects that the prevalence of hepatitis C will shrink in the coming decades thanks to new medicines and increased screening regimens. Currently, approximately one in 100 people are infected with the virus, and researchers expect that number to drop to about one in 1,500 people by 2036 if patients have timely and affordable treatment. “We were pleasantly surprised that in the next 22 years we could Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”

New York Times Building

Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the attention the cost has received to date, those attacking the drug are “looking at the costs of Sovaldi in the wrong way.” Sanger-Katz acknowledges that these one-time treatments can be a ‘shock to the system,’ but notes the value far outweighs the expense since it cures the disease in the majority of patients, preventing further costly treatments and care. Sanger-Katz Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Treating Hepatitis C: Too Costly Not to Act

CHI

Today, The Hill published an op-ed – Treating hepatitis C: Too costly not to act – by California Healthcare Institute’s Todd Gillenwater on the value of breakthrough Hepatitis C medicines that cure the disease in the majority of patients. As Gillenwater asserts, “New hepatitis C drugs mark a paradigm shift – from a model of somewhat iffy but costly chronic care to a model of short-term curative treatment with equal or slightly lower costs paid Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

Todd

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original intent, leading to evidence of abuse and potentially harmful consequences for patients. “The original intent of 340B was to support the most vulnerable patients; clearly that is not the focus for many of the participants in the program now,” said Todd. Todd pointed to three primary reasons the program needs more oversight: Exponential growth, significant violations revealed in audits, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

AIR 340B New Report: Contract Pharmacy Growth in 340B

AIR 340B

Today, the Alliance for Integrity and Reform of 340B (AIR 340B) released a white paper – The Impact of Growth in 340B Contract Pharmacy Arrangements – showingthat rapid contract pharmacy growth in the 340B program may not directly benefit the vulnerable patients for whom the program is intended. The paper highlights the growth of thousands of for-profit retail pharmacies – many of which are located in wealthier areas of the country. As of January 2014, Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,